Finding new drugs to slow down Alzheimer's disease progression.
Discovery and development of OGG1 activators as precision drugs for modification of Alzheimer's disease progression.
This study is looking for ways to help your body repair damage to the DNA in your cells, which can be a big part of Alzheimer's disease, with the hope of slowing down the disease's progression and improving your overall brain health.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Luciole Pharmaceuticals, INC. NIH-funded |
| Lab location | 1 site (Sherborn, UNITED STATES) |
| Project ID | NIH-10930103 on NIH RePORTER |
What this research studies
This research focuses on developing activators for the OGG1 enzyme, which plays a crucial role in repairing oxidative damage to mitochondrial DNA, a key factor in Alzheimer's disease progression. By enhancing the body's ability to repair this damage, the research aims to address the underlying causes of Alzheimer's rather than just alleviating symptoms. The approach involves understanding the mechanisms of oxidative stress and mitochondrial dysfunction in Alzheimer's patients and testing new compounds that could improve mitochondrial health. Patients may be monitored for changes in disease progression through innovative biomarkers.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who are diagnosed with Alzheimer's disease.
Not a fit: Patients with other forms of dementia or those under 21 years old may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new precision drugs that significantly slow the progression of Alzheimer's disease.
How similar studies have performed: While there have been various approaches to treating Alzheimer's, targeting base excision repair of oxidative damage is a novel and untested strategy.
Where this research is happening
Sherborn, UNITED STATES
- Luciole Pharmaceuticals, INC. — Sherborn, United States (Active)
Researchers
- Principal investigator: Rumsey, William L — Luciole Pharmaceuticals, INC.
- Study coordinator: Rumsey, William L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.